Speakers 2022

George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

George leads Synthetic Biology at the Wyss Institute and is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005.

George Church

Professor of Genetics, Harvard Medical School

Michael Greve is the  founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures. 

With his own team, he produces scientific papers that can be thought of as a screenshot of current world knowledge on a topic - each paper based on about 2000 abstracts and 150 studies. He publishes them in a database on his website, freely accessible to anyone at any time, comprehensively transformed into practical advice.
He has turned himself into the leading global figure of a new approach to longevity: he talks about rejuvenation, the preservation and restoration of youth. He talks about viewing the process of aging as a treatable disease, not an inescapable fate. All this not with the goal of eternal life, but of prolonging the healthy life span as much as possible.

Michael Greve

Founder at Forever Healthy Foundation

Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Ageing. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).​

Dr. Verdin studies how metabolism, diet, and small molecules impact epigenetic regulatory mechanisms, and thereby the ageing process and its associated diseases. He is a highly cited scientist (top 1 percent) and has been recognized for his research with multiple awards including a fellowship from the American Association for the Advancement of Science, election to the American Society for Clinical Investigation, the Association of American Physicians, and Belgium’s Royal Academy of Medicine.

Dr. Eric Verdin

President & CEO, Buck Institute for Research on Aging

Dr. Aubrey de Grey is the Chief Science Officer of SENS Research Foundation. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in ageing.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Ageing Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives talks at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Dr. Aubrey de Grey

Chief Science Officer, SENS Research Foundation

Dr. Wei-Wu He has been serving as Executive Chairman of Human Longevity Inc. since July 2019. Dr. He is currently the Chairman of CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder of Genetron Health; Dr. He also is the Founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established in 2000.

In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author of more than 50 research publications and inventor of over 32 issued patents. Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.

Wei-Wu He

Executive Chairman, Human Longevity Inc. Chairman and CEO, CASI Pharmaceuticals, Inc. Chairman and founder, Genetron Health.

Alex Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. 

He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. 

He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Alex Zhavoronkov

Founder and CEO at Insilico Medicine

As Editor-in-Chief of Longevity.Technology Phil oversees daily news and market research to address the crossover between longevity science and investment. This news platform has fast become the #1 for daily news and insights.

As founder of First Longevity Phil and his team help to prepare longevity science and technology businesses for equity funding ahead of introducing deals to, and syndicating deals among, VCs, family offices, and HNWs.

Prior to focusing exclusively on longevity, Phil has applied his marketing and business development expertise at c-level into: IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability markets.

Phil Newman

Founder, First Longevity, Editor-in-Chief Longevity.Technology

Prof. Evelyne Bischof is a Chief Physician Associate of Internal Medicine at University Hospital Renji of Jiaotong University Shanghai and concierge longevity physician for executive longevity patients.

Her research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. She published over 80 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe. 

Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc. Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice.

Prof. Evelyne Yehudit Bischof, MD, MPH, FEFIM, FMH

Associate professor, internal medicine specialist, Longevity physician at Human Longevity Inc.

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.

He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.

Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

Dr. Nir Barzilai

Director, Institute for Aging Research, Albert Einstein College of Medicine